'The data we'll be presenting at ASCRS showcases our continued commitment to innovate and provide additional treatment options for patients with eye conditions like presbyopia and glaucoma,' said
At the meeting, researchers will present new studies on the safety and efficacy of VUITY in a variety of settings. Notable data will include a post-hoc analysis evaluating the use of VUITY in participants with moderate to advanced presbyopia and a new analysis evaluating the onset of efficacy in participants with presbyopia. AbbVie will also present an analysis evaluating intermediate vision for presbyopia patients treated with VUITY.
Additionally, new analyses from studies assessing the safety and efficacy of the XEN Gel Stent will be presented. The XEN Glaucoma Treatment System is indicated for the surgical management of refractory glaucoma, including cases where previous surgical treatment has failed; cases of primary open angle glaucoma; and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy. The XEN Gel Stent is FDA-cleared for insertion via an ab interno approach; ab externo insertion of XEN Gel Stent is investigational and the safety and efficacy of this approach have not been evaluated by the FDA.
About VUITY
VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHast technology, which allows VUITY to rapidly adjust to the physiologic pH of the tear film. This was studied in simulated tear film, and the clinical significance is unknown. VUITY uses the eye's own ability to reduce pupil size and improves near and intermediate vision without compromising distance vision.
About Allergan Eye Care
As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry for more than 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of
Contact:
Media
T: +1 (714) 246-3843
E: lisa.kim@abbvie.com
(C) 2022 Electronic News Publishing, source